All In Biotech

Drug Trial Radar · NCT02759315

Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)

A Phase II, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682 + MK-8408 in Subjects With Chronic HCV Genotype 1, 2, 3, 4, 5 or 6 Infection

Last checked: Nov 20, 2026Latest source record: Jun 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

160

Actual

Start

May 3, 2016

Primary completion

Jul 27, 2017

Study completion Nov 16, 2017

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 3, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic hepatitis C virus (HCV) genotype (GT)1, GT2, GT3, GT4, GT5, or GT6 infection. The impact of the study treatment regimen on the percentage of participants with undetectable HCV ribonucleic acid \[RNA\] 12 weeks after completing study treatment (SVR12) will be evaluated.

Conditions

  • Hepatitis C, Chronic

Interventions

  • Uprifosbuvir 450 mgDrug

    450 mg administered as 3 x 150 mg oral tablets

  • Ruzasvir 60 mgDrug

    60 mg administered as 6 x 10 mg oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)Time frame: Week 24 (12 weeks after completing study therapy)
  2. Percentage of Participants With ≥1 Adverse Events (AEs)Time frame: Up to Week 14 (up to 2 weeks after completing study therapy)
  3. Percentage of Participants Withdrawing From Study Therapy Due to an AETime frame: Up to Week 12
  4. Percentage of Participants With ≥1 Events of Clinical Interest (ECIs)Time frame: Up to Week 14 (up to 2 weeks after completing study therapy)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.